0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanobac Pharmaceuticals
Its shares trade under the ticker NNBP. It has been listed since 21 June 2001. In the fiscal year to 31 December 2007, it reported revenue of $17,621 and a net loss of $6.6m. At that date it held total assets of $7.2m and shareholders' equity of −$2.4m.
Nanobac Pharmaceuticals, Inc. owns and operates community health centers. The company is headquartered in Tampa, Florida. The company went IPO on 2001-06-21. The firm is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Jun 2001
- Employees
- 1
Leadership
Pay as last reported
- John StantonChairman of the Board, Chief Executive Officer, Chief Financial Officer, since 2000
- Alexander EdwardsDirector, since 2003$8,874
- Dr. Benedict ManiscalcoDirector$87,500
- Dr. Stephen RechtschaffenDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nanobac Pharmaceuticals Inc has a strong portfolio of innovative pharmaceutical products.
- The company has a talented and experienced research and development team.
- Nanobac Pharmaceuticals Inc enjoys a good reputation in the industry for its quality products.
- The company has established strategic partnerships with key industry players.
Weaknesses
- Nanobac Pharmaceuticals Inc faces intense competition in the pharmaceutical market.
- The company has limited financial resources for expanding its operations.
- There are regulatory challenges and uncertainties that impact the company's product development and commercialization.
- Nanobac Pharmaceuticals Inc has a relatively small market share compared to its larger competitors.
Opportunities
- The growing demand for pharmaceutical products globally presents significant opportunities for Nanobac Pharmaceuticals Inc to expand its market presence.
- Advancements in medical technology open up avenues for the development of new and more effective pharmaceutical solutions.
- The company can diversify its product offerings to target new therapeutic areas and customer segments.
- Nanobac Pharmaceuticals Inc can explore potential collaborations and partnerships to enhance its research capabilities and market reach.
Threats
- Increasing regulatory scrutiny and stringent regulations pose a threat to the company's product development and commercialization efforts.
- Nanobac Pharmaceuticals Inc faces the risk of intellectual property infringement and competition from generic drug manufacturers.
- Market volatility and economic downturns can impact the company's financial performance and ability to attract investments.
- Emerging healthcare trends and changes in government policies may disrupt the pharmaceutical industry, creating uncertainties for Nanobac Pharmaceuticals Inc.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.